Pharma Focus Europe

Sarah Cannon Research Institute Expands into East Tennessee through Partnership with Tennessee Cancer Specialists

Friday, May 24, 2024

The Sarah Cannon Research Institute (SCRI), a leader in oncology research and community-based clinical trials, has announced a collaboration with Tennessee Cancer Specialists, an independent oncology practice in Knoxville, Tennessee. This partnership aims to provide enhanced research opportunities for cancer patients throughout East Tennessee.

"Our physicians have long valued the importance of clinical trials and the advanced treatment options they offer our patients," said Dr. Tracy W. Dobbs, President and oncologist at Tennessee Cancer Specialists. "We have been referring patients to SCRI in Nashville for many years, and we are excited to now offer these innovative therapies directly in our community."

Tennessee Cancer Specialists is the third largest oncology practice in Tennessee, with 12 physicians across 15 locations in East Tennessee.

"We look forward to partnering with Tennessee Cancer Specialists to further our mission of bringing clinical trials into the community," said Dee Anna Smith, CEO of SCRI. "This collaboration will allow patients to access new therapies without needing to travel far, enabling them to stay close to their homes and support networks."

SCRI’s research network includes over 1,300 physicians who enroll patients in clinical trials at more than 250 locations across 24 states. Since its inception, SCRI has conducted over 750 first-in-human clinical trials and contributed to the development of many new cancer therapies approved by the FDA.

Starting in the summer of 2024, Tennessee Cancer Specialists will begin offering clinical trials in collaboration with SCRI.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024